Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Author:
Affiliation:
1. Memorial Sloan Kettering Cancer Center, New York, New York
2. Weill Cornell Medicine, New York, New York
Publisher
American Medical Association (AMA)
Subject
General Medicine
Link
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2755853/iyengar_2019_oi_190615.pdf
Reference22 articles.
1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.;Slamon;Science,1987
2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.;Agus;Cancer Cell,2002
3. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.;Cho;Nature,2003
4. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.;Franklin;Cancer Cell,2004
5. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.;Baselga;N Engl J Med,2012
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study;Cancer Research and Treatment;2023-12-20
2. Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS);Cancer Science;2022-07-23
3. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer;Breast Cancer Research and Treatment;2021-07-24
4. First-line Gemcitabine Versus Treatment of Physician’s Choice for Metastatic Breast Cancer: A Prospective Cohort Study;Anticancer Research;2021-03
5. Efficacy and toxicity in scheduled intravesical gemcitabine versus Bacille Calmette-Guérin for Ta and T1 bladder cancer: a systematic review and meta-analysis;Translational Cancer Research;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3